Similarly, in pancreatic cancer cell line BxPC-3 and squamous cell carcinoma cell line PAM-LY2, which present high level of constitutive NF-κB activity, NF-κB was inhibited by the treatment with MG-132 and bortezomib, respectively [27, 28]. The gene discussed is NFKB1; the disease is squamous cell carcinoma.